This prospective cohort study aims to assess the efficacy and safety of the extended treatment with Sulodexide (Vessel) in the secondary prevention of DVT / PE recurrence in elderly outpatients ( 75 years old at the time of inclusion) ), with at least one of the known bleeding risk factor, who had a first episode of lower extremity proximal DVT and / or PE, idiopathic or associated with weak or removed risk factors, and who have received standard treatment with any oral anticoagulant drug lasting at least 3 months. The study seeks to verify the safety of the Sulodexide therapy, demonstrating non-inferiority compared to placebo, with an incidence of major bleeding around 1% (upper confidence limit not > 3%).
How understandable was the trial content above?
Hard to understand
Easy to understand
